Literature DB >> 23720365

Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Jenna Anderson1, Sara Hägglund, Emmanuel Bréard, Loic Comtet, Karin Lövgren Bengtsson, John Pringle, Stéphan Zientara, Jean Francois Valarcher.   

Abstract

Bluetongue virus (BTV), the causative agent of bluetongue in ruminants, is an emerging virus in northern Europe. The 2006 outbreak of BTV serotype 8 (BTV-8) in Europe was marked by an unusual teratogenic effect and a high frequency of clinical signs in cattle. Conventional control strategies targeting small ruminants were therefore extended to include cattle. Since cattle were not routinely vaccinated before 2006, the immune responses to BTV have not been studied extensively in this species. With the aims of developing a subunit vaccine against BTV-8 for differentiation between infected and vaccinated animals based on viral protein 7 (VP7) antibody detection and of improving the current understanding of the immunogenicity of BTV proteins in cattle, the immune responses induced by recombinant VP2 (BTV-8) and nonstructural protein 1 (NS1) and NS2 (BTV-2) were studied. Cows were immunized twice (with a 3-week interval) with the experimental vaccine, a commercial inactivated vaccine, or a placebo. The two vaccines induced similar neutralizing antibody responses to BTV-8. Furthermore, the antibody responses detected against VP2, NS1, and NS2 were strongest in the animals immunized with the experimental vaccine, and for the first time, a serotype cross-reactive antibody response to NS2 was shown in cattle vaccinated with the commercial vaccine. The two vaccines evoked measurable T cell responses against NS1, thereby supporting a bovine cross-reactive T cell response. Finally, VP7 seroconversion was observed after vaccination with the commercial vaccine, as in natural infections, but not after vaccination with the experimental vaccine, indicating that the experimental vaccine may allow the differentiation of vaccinated animals from infected animals regardless of BTV serotype. The experimental vaccine will be further evaluated during a virulent challenge in a high-containment facility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23720365      PMCID: PMC3754508          DOI: 10.1128/CVI.00229-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  54 in total

Review 1.  Bluetongue vaccines: the past, present and future.

Authors:  V Bhanuprakash; B K Indrani; M Hosamani; V Balamurugan; R K Singh
Journal:  Expert Rev Vaccines       Date:  2009-02       Impact factor: 5.217

Review 2.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

3.  Immunologic response of sheep to inactivated and virulent bluetongue virus.

Authors:  J L Stott; T L Barber; B I Osburn
Journal:  Am J Vet Res       Date:  1985-05       Impact factor: 1.156

4.  Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.

Authors:  H Huismans; N T van der Walt; M Cloete; B J Erasmus
Journal:  Virology       Date:  1987-03       Impact factor: 3.616

5.  Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle.

Authors:  Regula Wäckerlin; Michael Eschbaumer; Patricia König; Bernd Hoffmann; Martin Beer
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

6.  Molecular basis of bluetongue virus neutralization.

Authors:  J Kahlon; K Sugiyama; P Roy
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

7.  A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1.

Authors:  J Anderson; P P Mertens; K A Herniman
Journal:  J Virol Methods       Date:  1993-07       Impact factor: 2.014

8.  Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.

Authors:  Michael Eschbaumer; Bernd Hoffmann; Patricia König; Jens P Teifke; Jörn M Gethmann; Franz J Conraths; Carolina Probst; Thomas C Mettenleiter; Martin Beer
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

9.  Temporal development of bluetongue virus protein-specific antibody in sheep following natural infection.

Authors:  M A Adkison; J L Stott; B I Osburn
Journal:  Vet Microbiol       Date:  1988-03       Impact factor: 3.293

10.  Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions.

Authors:  J Gethmann; K Hüttner; H Heyne; C Probst; M Ziller; M Beer; B Hoffmann; T C Mettenleiter; F J Conraths
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

View more
  5 in total

1.  Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals.

Authors:  Jenna Anderson; Emmanuel Bréard; Karin Lövgren Bengtsson; Kjell-Olov Grönvik; Stéphan Zientara; Jean-Francois Valarcher; Sara Hägglund
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

3.  The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Authors:  Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Eva Calvo-Pinilla; Alejandro Marín-López; Gema Lorenzo; Pedro Sánchez-Cordón; Sandra Moreno; Julio Benavides; Sarah Gilbert; Aitor Nogales; Javier Ortego
Journal:  J Virol       Date:  2021-11-17       Impact factor: 5.103

Review 4.  Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.

Authors:  Luis Jiménez-Cabello; Sergio Utrilla-Trigo; Natalia Barreiro-Piñeiro; Tomás Pose-Boirazian; José Martínez-Costas; Alejandro Marín-López; Javier Ortego
Journal:  Vaccines (Basel)       Date:  2022-07-14

5.  Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.

Authors:  Shiva J Jyothi; Sunil R Patil; Narasimha Y Reddy; Rao P Panduranga; Uma Madala; Gnana M Prakash; Kalyani Putty
Journal:  Onderstepoort J Vet Res       Date:  2020-10-08       Impact factor: 1.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.